Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LOBE.CNthis companyLobe Sciences Ltd.	CA$0.04	-1.57×	2.94×	0×	-0.32×	-29.7%	0.0%	0.0%	0.0%	-187.9%	-80.9%	-20.4%	0.12×	1.31×	-7×	3.13×	0.0%	2	-11.09	2	C
BNXT.CNBioNxt Solutions Inc.	CA$0.26	-10.76×	-8.07×	0×	-13.49×	-121.0%	0.0%	0.0%	0.0%	75.0%	172.2%	-6.9%	-0.63×	-0.98×	-4.2×	0.05×	0.0%	3	-88.15	2	C
CYBN.NECybin Inc.	CA$12.78	-1.59×	1.01×	0×	-0.54×	-62.3%	0.0%	0.0%	0.0%	-63.2%	-60.9%	-57.1%	0×	1.11×	-48.88×	9.52×	0.0%	3	8.63	2	C
HEAL.CNRestart Life Sciences Corp.	CA$0.08	-3.13×	3.29×	0×	-2.15×	-56.8%	0.0%	0.0%	0.0%	-108.0%	-87.8%	-16.9%	0.19×	1.01×	0×	3.67×	0.0%	3	-42.67	2	C
MDMA.CNPharmala Biotech Holdings Inc.	CA$0.17	-6.19×	5.47×	22.2×	-6.47×	-266.4%	-139.6%	-355.6%	-359.2%	-88.5%	-87.6%	-7.8%	0×	0.02×	0×	1.71×	0.0%	2	5.56	1	D+
PHRX.CNPharmadrug Inc.	CA$0.01	-4.17×	-0.92×	0×	-43.31×	-437.1%	0.0%	0.0%	0.0%	21.7%	-144.3%	-5.4%	-0.86×	-20.78×	-0.73×	0.02×	0.0%	2	-78.75	2	C
Peer median	—	-4.17×	1.01×	0×	-6.47×	-121.0%	0.0%	0.0%	0.0%	-63.2%	-87.6%	-7.8%	0×	0.02×	-0.73×	1.71×	0.0%	3	-42.67	2	—